Using focused ultrasound to improve delivery of anti-cancer therapy for brain tumors
Official title: ImmunoPET Evaluation of Focused Ultrasound-mediated Delivery and Immunomodulation by anti-CD47 Immunotherapy in the Setting of Current Standard-of-Care Treatment for Glioblastoma
Funded at University of Maryland Baltimore · NIH-11071947 · Data updated 2026-11-12
This study is exploring a new way to help treat glioblastoma by using focused ultrasound to open the blood-brain barrier, which could allow better delivery of a special therapy along with standard treatments, potentially giving patients more effective options for fighting this tough brain tumor.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $36,902 |
| NIH project number | 5F30CA284526-02 |
| Project ID | NIH-11071947 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing standard-of-care treatment.
✕Less likely to help
Patients with other types of brain tumors or those who are not eligible for standard treatments may not benefit from this research.
What this research studies
This research investigates a new approach to treat glioblastoma, a highly aggressive brain tumor, by using focused ultrasound technology to temporarily open the blood-brain barrier. This allows for better delivery of anti-CD47 immunotherapy alongside standard treatments. The study aims to evaluate how effectively this method can enhance the treatment of glioblastoma by improving the distribution of therapeutic agents within the tumor. Patients may benefit from this innovative technique that could lead to more effective treatment options.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of treatments for glioblastoma patients by enhancing drug delivery to the tumor.
How similar studies have gone: Previous studies have shown promising results using focused ultrasound for drug delivery in brain tumors, indicating potential for success with this approach.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Malla, Adarsha Prakash — University of Maryland Baltimore
- Study coordinator: Malla, Adarsha Prakash
Related research
Other NIH-funded projects on the same topics.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Understanding why some glioblastoma patients respond long-term to an ATL-DC vaccine
A study in glioblastoma patients exploring why a personalized vaccine made from a patient’s own tumor blood cells helps some people live longer.
-
Ultrasound-guided nanodroplets to boost cancer immunotherapy
A new ultrasound-activated nanoparticle approach aims to help the immune system better attack breast cancer by delivering immune-stimulating signals directly to tumors.
-
Sonodynamic therapy for recurrent glioblastoma using MRI-guided focused ultrasound and ALA
A new treatment combines a drug called 5-ALA with MRI-guided focused ultrasound to target recurrent glioblastoma tumors.
-
Immune-boosting treatment with ultrasound-assisted brain drug delivery for newly diagnosed glioblastoma
A phase 2A trial will test a patient-friendly approach that uses a skull-implantable ultrasound device plus tiny bubbles to help immune therapies reach brain tumors in people with newly diagnosed glioblastoma.
-
Enhanced delivery of neural stem cells to brain cancer with a biodegradable gel and focused ultrasound
A new treatment approach uses patient-friendly neural stem cells delivered over several months with a biodegradable gel and ultrasound to target glioblastoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.